Observational, prospective, 12-month cohort study to analyze changes in the cardiometabolic profile of switching to lurasidone in patients with schizophrenia. RESPECT study
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: ANGELINI PHARMA ESPAÑA, SLU
- Execution start: 16/03/2021
- End of execution: 30/03/2022
- IP: MANUEL LOPEZ PEREZ